Engineered Endothelial Cell Therapy AB-205 Tested in 42 Lymphoma Patients Receiving Stem Cell Transplants
A completed phase 1 trial tested AB-205, an engineered endothelial cell product, after autologous stem cell transplant in 42 adults with lymphoma. No results are posted.
Summary
AB-205 is a cell therapy from Angiocrine Bioscience. It is built to support the blood vessel lining, the endothelium, which is thought to help the body rebuild blood and immune cells after the intense chemotherapy that comes before a stem cell transplant. This phase 1, open-label, multi-center trial enrolled 42 adults with Hodgkin or non-Hodgkin lymphoma in chemo-sensitive remission. All of them were having high-dose therapy, with or without radiation, followed by an autologous stem cell transplant (their own cells). AB-205 was infused on Day 0, right after the stem cell transfusion. The trial ran from May 2019 to November 2021 and is listed as completed. The registry entry gives only the design, so there are no efficacy or safety results here. Phase 1 trials mainly assess safety and feasibility. This is an early step in regenerative medicine for recovery after cancer treatment, not evidence that AB-205 works.
Detailed Summary
Why this matters: High-dose chemotherapy followed by autologous stem cell transplant can cure or control lymphoma, but it damages the bone marrow, the gut lining, and the blood vessels that support tissue repair. Recovery can be slow and risky, and long-term effects on healthspan are a concern for survivors. Regenerative approaches that protect or rebuild the vascular niche are therefore of real interest.
What was studied: AB-205 is an investigational cell product from Angiocrine Bioscience. The sponsor describes it as engineered endothelial cells, meaning cells of the blood vessel lining. The registry abstract itself does not describe the mechanism, so the rationale given here is the general one for this product class. The trial was a phase 1, open-label, multi-center study in 42 adults with Hodgkin or non-Hodgkin lymphoma in chemo-sensitive remission. Participants underwent high-dose therapy, with or without radiation, and then received their own stem cells. AB-205 was infused after the stem cell transfusion on Day 0.
Key results: There are none to report. The record lists the trial as completed, with a start of May 7, 2019 and a completion of November 8, 2021, but the abstract contains no safety, engraftment, recovery or survival data. Nothing is known here about mechanism, function or lifespan outcomes.
Implications: Completion of a 42-person phase 1 study means the concept reached human testing. Phase 1 designs mostly address safety, tolerability and dosing, so any later efficacy claim would need controlled phase 2 or 3 trials. The idea of supporting the vascular niche to speed tissue recovery is a mechanism worth watching.
Caveats: This summary is based only on the registry abstract. It has no outcome data, no comparison group, and no safety information. Readers and clinicians should not treat it as evidence of benefit.
Key Findings
- Phase 1, open-label, multi-center trial of AB-205 enrolled 42 adults with Hodgkin or non-Hodgkin lymphoma.
- AB-205 was infused on Day 0 after autologous stem cell transfusion following high-dose therapy.
- Trial status is completed, running May 2019 to November 2021, sponsored by Angiocrine Bioscience.
- The registry abstract reports no safety or efficacy results, so benefit and harm are unknown.
Methodology
Single-arm, open-label, multi-center phase 1 trial with 42 participants in chemo-sensitive remission undergoing high-dose therapy and autologous transplant. The intervention was one AB-205 infusion on Day 0. Endpoints are not stated in the abstract.
Study Limitations
This summary is based on the registry abstract only; the full record and any posted results were not available. There are no outcome data, no control group, and no safety information, and a phase 1 design cannot show efficacy.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe:
